🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in India / NCT07794579
Starting soon Phase 3

A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity

NCT07794579 · tracked via the Priya Life Science India tracker
Sponsor
Eli Lilly and Company
Phase
Phase 3
Started
2026-09
Last updated
2026-08-31

Condition(s) studied

OverweightPrediabetic StatePrehypertensionObesity, Abdominal

Investigational drug(s) / intervention(s)

OrforglipronPlacebo

Orforglipron: Administered orally

Placebo: Administered orally

Study summary

This study will evaluate the efficacy and safety of orforglipron in participants with overweight and assess whether it helps reduce the future risk of obesity-related conditions, including type 2 diabetes, hypertension, and dyslipidemia, and progression to class 1 obesity.

Eligibility

Sex
ALL
Min age
18 Years
Max age
Healthy volunteers
No
Inclusion Criteria: * Have an increased waist-to-height ratio of ≥0.5 * Have at least one pre-obesity-related complication (prediabetes, prehypertension, predyslipidemia) * Have at least one unsuccessful attempt to reduce body weight based on diet and exercise * Have a BMI greater than or equal to 25 to less than or equal to 29.9 kg/m2 or equivalent-/region-specific overweight thresholds Exclusion Criteria: * Have type 1 diabetes, type 2 diabetes, or any other type of diabetes * Do not have a stable body weight within 90 days before screening * Have a documented obesity diagnosis or self-reported history of BMI ≥30 kg/m² (or an equivalent region-specific threshold) * Have taken medications for weight loss, including over-the counter medications or alternative therapies, within 180 days prior to screening * Have a prior or planned surgical treatment or procedure for obesity * Have hypertension or history of hypertension * Have dyslipidemia or history of dyslipidemia

Primary outcome measure(s)

Trial sites (179)

FacilityCityRegionStatus
Pinnacle Research Group, LLC Anniston Alabama
Central Research Associates Birmingham Alabama
Cahaba Research - Pelham Pelham Alabama
Care Access - 801 South Power Road, Mesa Mesa Arizona
Absolute Clinical Research Phoenix Arizona
Synexus Clinical Research US, Inc./Orange Grove Family Practice Tucson Arizona
Orange County Research Center Lake Forest California
Healthy Brain Clinic Long Beach California
Los Angeles Institute for Metabolic Research Los Angeles California
Desert Oasis Healthcare Medical Group Palm Springs California
Artemis Institute for Clinical Research Riverside California
Riverside Clinical Riverside California
Headlands Research- Sacramento Sacramento California
Norcal Endocrinology & Internal Medicine San Ramon California
Diablo Clinical Research, Inc. Walnut Creek California
Yale University School of Medicine New Haven Connecticut
Chase Medical Research, LLC Waterbury Connecticut
Excel Medical Clinical Trials Boca Raton Florida
Flourish Research Acquisition, LLC dba Flourish Research - North Miami Miami Florida
New Age Medical Research Corporation Miami Florida
Renstar Medical Research Ocala Florida
Headlands Research Orlando Orlando Florida
Oviedo Medical Research Oviedo Florida
Care Access - St. Petersburg St. Petersburg Florida
Precision Clinical Research Sunrise Florida
SKY Clinical Research Network Group-Brown Atlanta Georgia
HOPE Clinical Research & Wellness Conyers Georgia
Care Access - Dalton Walmart Dalton Georgia
Care Access - Decatur Decatur Georgia
Family First Medical Center Idaho Falls Idaho
Solaris Clinical Research Meridian Idaho
Great Lakes Clinical Trials - Ravenswood Chicago Illinois
Iowa Diabetes and Endocrinology Research Center West Des Moines Iowa
Cotton O'Neil Clinical Research Center Topeka Kansas
Monroe Biomedical Research - Louisville Louisville Kentucky
Pennington Biomedical Research Center Baton Rouge Louisiana
IMA Clinical Research Monroe-Main Monroe Louisiana
Centennial Medical Group Columbia Maryland
Brigham and Women's Hospital Diabetes Program Boston Massachusetts
Great Lakes Research Group, Inc. Bay City Michigan

+ 139 more sites — see the full list on the official registry below.

More Eli Lilly and Company trials in India

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07794579 on ClinicalTrials.gov ↗ ← All trials in India